期刊文献+

氟伏沙明对N2a细胞mTOR、Camk2γ及GSK-3β表达的影响

Effects of fluvoxamine on expressions of mTOR,Camk2γ and GSK-3β in N2a cells
原文传递
导出
摘要 目的探讨氟伏沙明对N2a细胞雷帕霉素靶蛋白(mTOR)、钙/钙调素依赖性蛋白激酶2γ(Camk2γ)及糖原合酶激酶3β(GSK-3β)表达的影响及其可能机制。方法将培养成功的N2a细胞随机分为3组,每组6个复孔,分别加入DMEM(D组)、氟伏沙明0.5μmol/L(F组)和BD1047(σ1受体阻断剂)0.2μmol/L+氟伏沙明0.5μmol/L(BF组)培养48h。Western blot检测各组mTOR、Camk2γ及GSK-3β的表达。结果与D组相比,F组mTOR及Camk2γ表达上调,GSK-3β表达下调(P<0.01);与F组相比,BF组mTOR及Camk2γ表达下调,GSK-3β表达上调(P<0.01)。结论氟伏沙明的药理作用可能与激活σ1受体活性有关。 Objective To study the effects and underlying mechanisms of fluvoxamine on the expressions of mammalian target of rapamycin(mTOR),Caz+/calmodulin-dependent protein kinase 27 (Camk27) and glycogen synthase kinase 313(GSK-3) in cultured N2a cells. Methods The cultured N2a cells were randomly divided into 3 groups with 6 samples each. The NZa cells in group D were treated with DMEM, those in group F with fluvoxamine 0. 5 vmol/L, and those in group BF with BD1047(al receptor antagonist) 0.2 vmol/L plus fluvoxamine 0.5 /μmol/L. The expressions of mTOR,Camk27 and GSK-3 in the cultured N2a cells were detected by Western blot two days after incubation, respectively. Results Compared with group D, group F showed a significant increase in the expressions of mTOR and Camk27, and a decrease in the expression of GSK-3[^(P〈0. 01). Compared with group F,group BF showed a significant decrease in the expressions of roTOR and Camk27, and an increase in the expression of GSK-3 (P〈0. 01). Conclusion The pharmacological property of fluvoxamine is probably related to the activation of receptor.
出处 《江苏医药》 CAS 北大核心 2014年第2期132-134,共3页 Jiangsu Medical Journal
关键词 氟伏沙明 雷帕霉素靶蛋白 钙调素依赖性蛋白激酶2γ 糖原合酶激酶3Β σ1受体 Fluvoxamine Mammalian target of rapamycin Ca2+/calmodulin-dependentprotein kinase 27 Glycogen synthase kinase 3t3 ol receptor
  • 相关文献

参考文献12

  • 1汪春运,余琳.氟伏沙明在精神科的应用[J].医学研究生学报,2006,19(1):89-91. 被引量:18
  • 2Niitsu T, Fujisaki M, Shiina A, et al. A randomized, double- blind,placebo-controlled trial of fluvoxamine in patients with schizophrenia:a preliminary study[J]. J Clin Psychophar- macol, 2012,32(5) : 593-601.
  • 3Sugimoto Y, Tagawa N, Kobayashi Y, et al. Involvement of the sigma-1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine[J]. Eur J Pharmacol, 2012, 696 (1-3) : 96-100.
  • 4Gomes MP, Millen TA, Ferreira PS, et al. Prion protein com- plexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells [J]. J Biol Chem,2008,283(28) : 19616-19625,.
  • 5Niitsu T, lyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases[J]. Curr Pharm Des, 2012,18(7) : 875-883.
  • 6Hindmareh I, Hashimoto K. Cognition and depression:the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered[J]. Hum Psychopharmacol, 2010,25(3) : 193-200.
  • 7Hashimoto K. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia[J]? CNS Neurol Disord Drug Targets, 2009,8(6) : 470-474.
  • 8Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy[J]. J Neurosci, 2009,29(21) : 6964-6972.
  • 9Kitagishi Y, Kobayashi M, Kikuta K, et al. Roles of PI3K/ AKT/GSK3/mTOR pathway in cell signaling of mental illnesses[J]. Depress Res Treat, 2012,20 (12): 7525-7563.
  • 10Tombes RM, Faison MO, Turbeville JM. Organization and evolution of muhifunetional Ca^2+/CaM-dependent protein kinase genes[J]. Gene, 2003,322 (11) : 17-31.

二级参考文献18

  • 1Lucki I,O'Leary OF.Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs[J].J Clin Psychiatry,2004,65 (Suppl 4):11-24.
  • 2Lu ML,Lane HY,Lin SK,et al.Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances[J].J Clin Psychiatry,2004,65 (6):766-771.
  • 3Howell HB,Brawman-Mintzer OB,Monnier J,et al.Generalized anxiety disorder in women[J].Psyehiat Clin North Am,2001,24(1):165-178.
  • 4Kjernisted KD,Bleau P.Long-term goals in the management of acute and chronic anxiety disorders[J].Can J Psychiatry,2004,49(Suppl 1):51-63.
  • 5Damsa C,Bianchi-Demicheli F,Vidailhet P,et al."Dopamine-dependent" side effects of selective serotonin reuptake inhibitors:a clinical review[J].J Clin Psychiatry,2004,65(8):1064-1066.
  • 6Owens MJ.Selectivity of antidepressants:from the monoamine hypothesis of depression to the SSRI revolution and beyond[J].J Clin Psychiatry,2004,65 (Suppl 4):5-10.
  • 7Schatzberg AF.New approaches to managing psychotic depression[J].J Clin Psychiatry,2003,64 (Suppl 1):19-23.
  • 8Findling RL,Feeny NC,Stansberg RL,et al.Somatic treatment for depressive illnesses in children and adolescents[J].Psychiatr Clin North Am,2004,27(1):113-137.
  • 9Phillips KA,Najjar F.An open-label study of citalopram in body dysmorphic disorder[J].J Clin Psychiatry,2003,64(6):715-720.
  • 10Saxena S,Winograd A,Dunkin JJ,et al.A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder[J].J Clin Psychiatry,2001,62(1):67-72.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部